There may be a stronger case to invest in single stocks over exchange-traded funds in the weight loss space.
Amplify ETFs and Roundhill Investments each filed a prospectus last week to launch funds focused on weight loss companies, a move that Strategas ETF and technical strategist Todd Sohn believes hinges on the performance of two dominant stocks: "The main holdings are going to be Lilly and Novo Nordisk, and probably one or two other big names … along with some of the manufacturers down the supply chain," he told CNBC's. With just two players currently at the forefront of the U.S. obesity drug market, ProShares' Simeon Hyman questions the relevance of weight loss ETFs for investors looking to buy into the industry. "I think that's one of the challenges whenever you see an innovation like this," the firm's global investment strategist said in the same interview. "If the benefits are going to incumbents, then maybe there isn't a theme per se that needs to be exploited.
Investing Single Stocks Etfs Weight Loss Amplify Etfs Roundhill Investments Lilly Novo Nordisk Proshares
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: FXStreetNews - 🏆 14. / 72 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »